Torii

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Torii's Japan sales performance.

Sanofi/Regeneron wins another EU approval for Dupixent

the US and Japan.

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Approval comes after an accelerated review of the drug. Japan’s Astellas Pharma has won EU approval for Xospata, a drug to treat acute myeloid leukaemia associated with a mutation in ... times. Xospata has already been approved for this indication in

AZ reports growth again in Q3, driven by oncology and China sales

Another strong performance from our new medicines accompanied impressive results in our key markets, most notably in China, the US and Japan.

Novartis grows in Q3 thanks to stellar performance of key drugs

The therapy is currently under regulatory review in Europe and Japan, with decisions expected in 2020. ... The FDA in the US is still investigating the data manipulation – Novartis CEO Vas Narasimhan (pictured below) has said however that “for both

Roche scores another FDA approval for Xofluza

Roche holds worldwide rights to the drug, excluding Japan and Taiwan, which are retained exclusively by Shionogi.

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

COVID-19 Updates and Daily News

The search for treatments for Parkinson’s disease: The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.: Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials: As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...